A clinical study of the efficacy forecast role of IL-21 in interferon therapies for chronic hepatitis B.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002888

Enrollment

Unknown

Registered

2012-10-29

Start date

2012-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

HBeAg-positive:interferon-alpha

Eligibility

Sex/Gender

All

Age

16 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Males or females with age from 18 to 50 years old; 2. Chronic HBV infected patients based on diagnostic criteria of 2010 China clinical practice guidelines of chronic hepatitis B; 3. Comply with antiviral indications andno contraindications applying interferon-alpha; 4. To be able to understand and sign the informed consent.

Exclusion criteria

Exclusion criteria: The combined HAV, HCV, HDV, or other types of viral hepatitis; liver cirrhosis and hepatocellular carcinoma, metabolic liver disease, autoimmune hepatitis; pregnancy or breast-feeding; associated with other serious diseases (such as cancer, severe heart, lung, kidney, digestive diseases, mental illness, hyperthyroidism, diabetes, etc.); Applied interferon-a before one year without any antiviral treatment.

Design outcomes

Primary

Measure	Time frame
liver function;HBV DNA quantitation;blood routine;serum HBsAg quantitation;serum HBeAg quantitation;serum IL-21 quantitation;phenotype and numbers of immunocyte;	—

Contacts

Public ContactXiucheng Pan

xzpxc@126.com+86 13952267926

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026